MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - MYLAN (US)
VENUS REMEDIES vs MYLAN (US) - Comparison Results
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 VENUS REMEDIES  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
MYLAN Dec-18 |
VENUS REMEDIES/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 3,390 | - | |
| Low | Rs | 61 | 1,866 | - | |
| Sales per share (Unadj.) | Rs | 301.8 | 1,559.9 | - | |
| Earnings per share (Unadj.) | Rs | -24.9 | 42.4 | - | |
| Cash flow per share (Unadj.) | Rs | 2.5 | 334.4 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 293.3 | 1,687.5 | - | |
| Shares outstanding (eoy) | m | 12.34 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 1.7 | 18.4% | |
| Avg P/E ratio | x | -3.8 | 62.0 | -6.1% | |
| P/CF ratio (eoy) | x | 36.7 | 7.9 | 467.6% | |
| Price / Book Value ratio | x | 0.3 | 1.6 | 20.5% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,154 | 1,352,115 | 0.1% | |
| No. of employees | `000 | 0.9 | 35.0 | 2.6% | |
| Total wages/salary | Rs m | 393 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,026.1 | 22,930.8 | 17.6% | |
| Avg. wages/employee | Rs Th | 425.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | -331.8 | 622.7 | -53.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 802,578 | 0.5% | |
| Other income | Rs m | 23 | 0 | - | |
| Total revenues | Rs m | 3,747 | 802,578 | 0.5% | |
| Gross profit | Rs m | 395 | 207,678 | 0.2% | |
| Depreciation | Rs m | 338 | 150,274 | 0.2% | |
| Interest | Rs m | 354 | 38,601 | 0.9% | |
| Profit before tax | Rs m | -275 | 18,802 | -1.5% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 32 | -2,991 | -1.1% | |
| Profit after tax | Rs m | -307 | 21,793 | -1.4% | |
| Gross profit margin | % | 10.6 | 25.9 | 41.0% | |
| Effective tax rate | % | -11.5 | -15.9 | 72.1% | |
| Net profit margin | % | -8.2 | 2.7 | -303.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 448,159 | 0.6% | |
| Current liabilities | Rs m | 2,305 | 326,757 | 0.7% | |
| Net working cap to sales | % | 8.9 | 15.1 | 59.1% | |
| Current ratio | x | 1.1 | 1.4 | 83.4% | |
| Inventory Days | Days | 135 | 84 | 162.1% | |
| Debtors Days | Days | 46 | 93 | 49.6% | |
| Net fixed assets | Rs m | 4,871 | 155,687 | 3.1% | |
| Share capital | Rs m | 123 | 427 | 28.9% | |
| Net worth | Rs m | 3,619 | 868,243 | 0.4% | |
| Long term debt | Rs m | 1,374 | 937,113 | 0.1% | |
| Total assets | Rs m | 7,509 | 2,328,965 | 0.3% | |
| Interest coverage | x | 0.2 | 1.5 | 15.0% | |
| Debt to equity ratio | x | 0.4 | 1.1 | 35.2% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 143.9% | |
| Return on assets | % | 0.6 | 2.6 | 24.3% | |
| Return on equity | % | -8.5 | 2.5 | -337.8% | |
| Return on capital | % | 1.6 | 3.2 | 49.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 166,776 | 0.3% | |
| From Investments | Rs m | -123 | -86,205 | 0.1% | |
| From Financial Activity | Rs m | -387 | -77,694 | 0.5% | |
| Net Cashflow | Rs m | 4 | 1,382 | 0.3% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.22 Rs / USD
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare VENUS REMEDIES With: ALKEM LABORATORIES SUVEN LIFESCIENCES PFIZER WOCKHARDT CADILA HEALTHCARE
|
| |
Today's Market
Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)
After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?
Related Views On News
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Two Stocks to Buy in the Great Indian Festival (Profit Hunter)
Oct 11, 2019Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.
Buy these 3 Stocks for Rebound Riches
Oct 18, 2019Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...
The One Stock I Like in this Market (The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
More|
| |
VENUS REMEDIES SHARE PRICE
Oct 18, 2019 (Close)
TRACK VENUS REMEDIES
- Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON VENUS REMEDIES
VENUS REMEDIES 5-YR ANALYSIS
COMPARE VENUS REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.